Literature DB >> 479737

Large-scale preparation of highly purified pyrogen-free human growth hormone for clinical use.

R L Jones, G Benker, P R Salacinski, T J Lloyd, P J Lowry.   

Abstract

A method is described for the large-scale isolation of highly purified human growth hormone for therapeutic use. The hormone was extracted from frozen pituitary glands under mildly alkaline conditions. Purification was effected by gel filtration and ion-exchange chromatography. The final product was pyrogen-free and had a potency of 2.5 i.u./mg measured by bioassay against the current international standard. The yield of growth hormone/gland was approximately 5 mg.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 479737     DOI: 10.1677/joe.0.0820077

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  10 in total

1.  Reversal of H-2-restricted hyporesponsiveness to human growth hormone by the use of aluminum hydroxide as adjuvant.

Authors:  R Bomford; R Aston; J Ivanyi
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

2.  Application of ELISA for assessment of antiserum immunoreactivity in endocrine immunocytochemical studies.

Authors:  A C Nierwenhuijzen Kruseman
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

Review 3.  Perspectives on long-acting growth hormone therapy in children and adults.

Authors:  Rayhan A Lal; Andrew R Hoffman
Journal:  Arch Endocrinol Metab       Date:  2019 Nov-Dec       Impact factor: 2.309

Review 4.  Etiology and pathogenesis of prion diseases.

Authors:  S J DeArmond; S B Prusiner
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

5.  The heterogeneity of bovine growth hormone. Extraction from the pituitary of components with different biological and immunological properties.

Authors:  I C Hart; L A Blake; P M Chadwick; G A Payne; A D Simmonds
Journal:  Biochem J       Date:  1984-03-01       Impact factor: 3.857

6.  A further British case of growth hormone induced Creutzfeldt-Jakob disease.

Authors:  C J Ellis; H Katifi; R O Weller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

7.  Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human growth hormone? Inactivation experiments with the 263K strain of scrapie. Rapid communication.

Authors:  M Pocchiari; G Macchi; S Peano; A Conz
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

8.  Hydrophobic-interaction chromatography and anion-exchange chromatography in the presence of acetonitrile. A two-step purification method for human prolactin.

Authors:  S C Hodgkinson; P J Lowry
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

9.  Long-Acting Growth Hormone Preparations in the Treatment of Children.

Authors:  Rayhan A Lal; Andrew R Hoffman
Journal:  Pediatr Endocrinol Rev       Date:  2018-09

10.  Antigenic, receptor-binding and mitogenic activity of proteolytic fragments of human growth hormone.

Authors:  R Aston; J Ivanyi
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.